Q3 China Pharma Revenues Recover After Lockdown Disruptions

 
• By Dexter Jie Yan

Following disruptions in the second quarter from lockdowns around China, major Chinese firms BeiGene and Junshi reported strong double-digit sales gains for anti-PD-1 antibodies in the third quarter. Revenues at others including Hengrui, Zai Lab and Allist also shone during the period.

China pharmas 3Q sales
Chinese drug makers mostly rid of COVID-19 impacts in Q3 • Source: Shutterstock

More from China

More from Focus On Asia